Regulatory Story
Go to market news section View chart   Print
RNS
Consort Medical PLC  -  CSRT   

Interim Management Statement

Released 07:00 18-Mar-2013

RNS Number : 1651A
Consort Medical PLC
18 March 2013
 



 

News Release

 

18 March 2013

 

Consort Medical plc

 

Interim Management Statement

 

Consort Medical plc ("Consort" or "The Group") (LSE: CSRT), today issues its Interim Management Statement for the period from 1 November 2012 to date. 

                       

The Group is trading in line with its expectations and the Board remains confident of the outlook for the full year.

 

Bespak has continued to make good progress with its broad development portfolio, with a number of launches scheduled over the next twelve months.

 

In particular:

·     Project DEV750, a DPI (dry powder inhaler) device for a European Pharma, has launched. The Chiesi FOSTER® NEXThaler® dry powder inhaler offers new treatment options for patients suffering from asthma. This follows the regulatory approval granted in 14 European countries in Q4 2012 and completes the range of dosage forms of Chiesi's successful Foster® drug. The first launch market is Germany;

·     Following the commercial contract award from Nicoventures (as announced 3 December 2012), good progress has been made in product industrialisation, in facilities planning, and in process preparation;

·     The industrialisation for volume manufacture of the Atlas Genetics POC test cartridge (POC010) is progressing well. The opportunity for Consort to subscribe to the second tranche of Atlas Genetics' equity funding will be in April 2013. The Consort Board intends to take up its option in full, to invest a further £1.1 million equity into Atlas Genetics.

 

The King Systems disposal completed on 15 February, a few weeks earlier than originally anticipated. We are currently in the middle of the completion accounts process, which is expected to conclude in mid-April. Under the terms of the sale of the King Systems business, Consort has an earn-out based on the King Vision product development and sales. Against both of these criteria, the business performed in line with our expectations in the period up to the date of completion. 

 

Following the completion of the disposal of King Systems, there has been a favourable change in the Group's consolidated financial position. The initial consideration of $125 million (£80.6 million) was received on 15 February 2013: this is subject to a post-completion adjustment for actual working capital and actual net indebtedness at completion. At 28 February 2013 the Group net cash balance was £39.0 million.

 

-Ends-

 

Enquiries:

Consort
Jonathan Glenn - Chief Executive

Richard Cotton - Finance Director

Tel: +44 1442 867920

Brunswick Group

Jon Coles

Amie Gramlick

Tel: +44 20 7404 5959

 

 

 

 

Consort Medical plc is an international medical devices company, focused on developing and manufacturing disposable medical devices for drug delivery. The principal business of the Company is the management of Bespak, a global market leader in the manufacture of drug delivery devices for pharmaceutical partner companies, including respiratory nasal, and injectables products, and the manufacture of devices for the point of care diagnostics market.

 

The Group has facilities in King's Lynn, Cambridge, Nelson and Hemel Hempstead in the UK. Consort Medical is a public company quoted on the full list of the London Stock Exchange (LSE: CSRT). The Group's website address is www.consortmedical.com.

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSMMGMFVKNGFZM
Close


London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.

 


Interim Management Statement - RNS